ResMedMEX:RMD 99 PB Ratio is 4.60 as of Jun. 24, 2026, which is 38% below its 10-year median of 7.36. GuruFocus rates MEX:RMD with a GF Score™ of 99/100 and a GF Value™ of MXN5,298.64 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 787 Medical Devices & Instruments companies, ResMed ranks worse than 76.75% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-24), ResMed's share price is MXN3716.10. ResMed's Book Value per Share for the quarter that ended in Mar. 2026 was MXN807.13. Hence, ResMed's PB Ratio of today is 4.60.
Good Sign:
ResMed Inc stock PB Ratio (=4.27) is close to 10-year low of 4.21.
The historical rank and industry rank for ResMed's PB Ratio or its related term are showing as below:
MEX:RMD'
s PB Ratio Range Over the Past 10 Years
Min: 4.21 Med: 7.36 Max: 14.93
Current: 4.27
During the past 13 years, ResMed's highest PB Ratio was 14.93. The lowest was 4.21. And the median was 7.36.
MEX:RMD's PB Ratio is ranked worse than 76.75% of 787
companies
in the Medical Devices & Instruments industry
Industry Median: 2.04
vs MEX:RMD: 4.27
During the past 12 months, ResMed's average Book Value Per Share Growth Rate was 18.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 21.10% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 18.90% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 13.40% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of ResMed was 64.80% per year. The lowest was -4.70% per year. And the median was 17.35% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
ResMed PB Ratio Related Terms
ResMed PB Ratio Historical Data
* Premium members only.
The historical data trend for ResMed's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, ResMed's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ResMed PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ResMed's PB Ratio distribution charts can be found below:
* The bar in red indicates where ResMed's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
ResMed's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
ResMed (MEX:RMD) has a PB Ratio of 4.60 as of Jun. 24, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on ResMed and its competitors. This is 38% below median its historical median of 7.36. Over the past decade, ResMed's PB Ratio has ranged from 4.21 to 14.93. According to the industry distribution chart, ResMed ranks #604 out of 787 companies in the Medical Devices & Instruments industry, placing it in the top 76.7%.
Is ResMed's PB Ratio too high?
ResMed's current PB Ratio of 4.60 is 38% below median its 10-year median of 7.36. Over the past 10 years, this metric has ranged from a low of 4.21 to a high of 14.93. The Medical Devices & Instruments industry median PB Ratio is 2.04. ResMed's value of 4.60 is 125.5% above this industry median. Based on the distribution chart, ResMed ranks #604 out of 787 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, ResMed has a GF Score™ of 99/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ResMed's PB Ratio compare to MDLN and WST?
According to the Medical Devices & Instruments industry distribution chart, ResMed ranks #604 out of 787 companies for PB Ratio. This places ResMed in the lower half of its industry. The industry median PB Ratio is 2.04. ResMed's value of 4.60 is 125.5% above this benchmark. Historically, ResMed's own PB Ratio has ranged from 4.21 to 14.93 over the past decade. While the company's 10-year median is 7.36 vs. the industry median of 2.04, ResMed has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.04, based on 787 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ResMed's current PB Ratio of 4.60 is 125.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on ResMed and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ResMed's current PB Ratio is 4.60, which is 38% below median its own 10-year median of 7.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ResMed stock overvalued right now?
Based on GuruFocus' analysis, ResMed (MEX:RMD) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN5,298.64, compared to a current price of MXN3,716.10 — trading 29.9% below its estimated fair value. The current PB Ratio is 4.60, which is 38% below median its 10-year median of 7.36 and 125.5% above the Medical Devices & Instruments industry median of 2.04. ResMed's overall GF Score™ is 99/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For ResMed (MEX:RMD), the current PB Ratio is 4.60 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ResMed (MEX:RMD) Overvalued in 2026?
Based on GuruFocus' analysis, ResMed stock appears to be undervalued.
The current stock price of MXN3,716.10 is trading 29.9% below its estimated GF Value™ of MXN5,298.64.
GuruFocus considers ResMed to be Significantly Undervalued.
Key valuation signals for MEX:RMD:
PB Ratio: 4.60 (38% below median its 10-year median of 7.36)
GF Value™: MXN5,298.64 vs. price of MXN3,716.10 (29.9% below fair value)
Industry Position: 125.5% above the Medical Devices & Instruments median (#604 of 787)
No single metric tells the full story. See the MEX:RMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
99GF Score
Get the complete analysis for MEX:RMD
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:RMD has been successfully added to your 
